This is a working overview of dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-04 and is reviewed periodically as new material appears.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
periodic table of the elements Also simply the periodic table. A tabular arrangement of the chemical elements organized by their atomic number, electron configuration, and other chemical properties, whose adopted structure shows periodic trends and is used by chemists to derive relationships between various elements as well as predict the properties and behaviors of undiscovered or newly synthesized elements. The first periodic table of the elements was published by Russian chemist Dmitri Mendeleev in 1869.
== Spectroscopy == Both the fluorescence excitation and emission spectrums of wild-type EosFP are shifted ~65 nm to the right upon excitation toward the red end of the spectrum. This spectral change is caused by an extension of the chromophore accompanied by a break in the peptide backbone between Phe-61 and His-62 in an irreversible mechanism. The presence of a crisp isosbestic point at 432 nm also suggests an interconversion between two species. An absorption peak at 280 nm is visible due to aromatic amino acids which transfer their excitation energy to the green chromophore. The quantum yield of the green-emitting form of Eos is 0.7. In the red shifted species, there are pronounced vibronic sidebands separate from the main peak at 533 nm and 629 nm in the excitation spectrum and emission spectrum respectively. There is another peak in the red excitation spectrum at 502 nm likely due to FRET excitation of the red fluorophore. The quantum yield of the red-emitting form is 0.55. EosFPs variants show almost no difference in spectroscopic properties, therefore, it is likely that the structural modifications which arise from separation of interfaces have little to no effect on the structure of the fluorophore-binding site.
=== Discontinued === 1-Amino-5-bromouracil (ABU) – undefined mechanism of action [60] ABT-418 – nicotinic acetylcholine receptor agonist [61] ABT-436 – vasopressin V1B receptor antagonist [62] Adipiplon (NG-273) – GABAA receptor positive allosteric modulator and nonbenzodiazepine [63] Alnespirone (S-20499) – serotonin 5-HT1A receptor agonist [64] Alosetron (GR-68755; GR-68755C; Lotronex) – serotonin 5-HT3 receptor antagonist [65] Alpidem (Ananxyl; S-800342-001; SL-800342) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/imidazopyridine [66] Alprazolam lingual spray – GABAA receptor positive allosteric modulator and benzodiazepine [67] AN-788 (IP-2018; NSD788) – serotonin–dopamine reuptake inhibitor (SDRI) [68] AP-521 – serotonin 5-HT1A receptor partial agonist [69] Aprepitant (Emend; L-754030; MK-0869; MK-869; ONO-7436) – neurokinin NK1 receptor antagonist [70] AVN-211 (CD-008-0173) – serotonin 5-HT6 receptor antagonist [71] AVN-397 – undefined mechanism of action [72] AZD-2327 – δ-opioid receptor (DOR) agonist [73] AZD-8129 (AR-A000002; AR-A2XX; AR-A2) – serotonin 5-HT1B receptor antagonist [74] Befloxatone (MD-370503) – reversible inhibitor of monoamine oxidase A (RIMA) [75] Blarcamesine (AE-37; ANA001; ANAVEX 2-73) – sigma σ1 receptor agonist, muscarinic acetylcholine M1 receptor agonist, and ionotropic glutamate NMDA receptor agonist [76] Bretazenil (RO-166028) – GABAA receptor positive allosteric modulator and benzodiazepine [77] Brofaromine (Brofaremine; CGP-11305A; Consonar; Consonev) – reversible inhibitor of monoamine oxidase A (RIMA) and serotonin reuptake inhibitor (SRI) [78] Buspirone transdermal (BuSpar Patch) – serotonin 5-HT1A receptor partial agonist and other actions [79] CGS-12066 – serotonin 5-HT1B receptor partial agonist and other actions [80] Coluracetam (BCI-540; MKC-231) – ionotropic glutamate AMPA receptor positive allosteric modulator, choline uptake and acetylcholine synthesis enhancer, and racetam [81] DAA-1097 – translocator protein (TSPO) agonist [82] Devazepide (Devacade; L-364718; MK-329) – Cholecystokinin A (CCKA) receptor antagonist [83] Dipraglurant (ADX-48621; mGluR5-NAM) – metabotropic glutamate mGlu5 receptor negative allosteric modulator [84] Eglumetad (eglumegad; LY-354740) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist [85] Emapunil (AC-5216; XBD173) – translocator protein (TSPO) agonist [86] Emicerfont (GW-876008; GW876008) – corticotropin releasing factor CRF1 receptor antagonist [87] Enciprazine (D-3112; WY-48624) – serotonin 5-HT1A receptor agonist and α1-adrenergic receptor ligand [88] Eplivanserin (Ciltyri; Sliwens; SR-46349; SR-46349B; SR-46615A) – serotonin 5-HT2A receptor antagonist [89] Eptapirone (F-11440) – serotonin 5-HT1A receptor agonist [90] Esprolol ((S)-ACC-9369) – beta blocker (β-adrenergic receptor antagonist) (amoxolol prodrug) [91] Flesinoxan (DU-29373) – serotonin 5-HT1A receptor agonist [92] Gabapentin (CI-945; Gabapen; GOE-3450; Neurontin) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) [93] Girisopam (EGIS-5810; GYKI-51189) – GABAA receptor positive allosteric modulator and benzodiazepine [94] GT-2203 – histamine H3 receptor agonist [95] Guanfacine (Guanfacine Carrier Wave project; SPD-554) – α2-adrenergic receptor agonist [96] Ipsapirone (BAY-Q-7821; TVX-Q-7821) – serotonin 5-HT1A receptor partial agonist [97] Isamoltane (CGP-361A) – beta blocker (β-adrenergic receptor antagonist) and serotonin 5-HT1A and 5-HT1B receptor antagonist [98] Itasetron (DAU-6215; U-98079) – serotonin 5-HT3 receptor antagonist [99] ITI-333 – serotonin 5-HT2A receptor antagonist, dopamine D1 receptor antagonist, α1A-adrenergic receptor antagonist, and μ-opioid receptor (MOR) partial agonist [100] JNJ-19567470 (CRA-5626; R-317573) – corticotropin releasing factor CRF1 receptor antagonist [101] Levetiracetam (Keppra; L-059; SIB-S1; UCB-059; UCB-22059; UCB-L059) – synaptic vesicle glycoprotein 2A (SV2A) ligand [102] Lorazepam intranasal – GABAA receptor positive allosteric modulator and benzodiazepine [103] Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist [104] Midazolam intranasal (ITI-111; midazolam nasal spray; Nayzilam; USL-261) – GABAA receptor positive allosteric modulator and benzodiazepine [105] MK-0777 (L-830982; TPA-023) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/triazolopyridazine [106] NBI-34041 (SB-723620) – corticotropin-releasing hormone (CRH) inhibitor [107] Nerisopam (EGIS-6775; GYKI-52322) – GABAA receptor positive allosteric modulator and benzodiazepine [108] Nivasorexant (ACT-539313; SORA) – orexin OX1 receptor antagonist [109] NS-11821 (NS11821) – GABAA receptor positive allosteric modulator and nonbenzodiazepine [110] Orvepitant (GW-823296; GW823296X) – neurokinin NK1 receptor antagonist [111] Osanetant (ACER-801; SR-142801; SR-142806) – neurokinin NK3 receptor antagonist [112] Panadiplon (FD-10571; FG-10571; NNC-140571; U-78875) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/pyrazolopyrimidine [113] Pazinaclone (A-77000; DN-2327) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [114] Pozanicline (A-87089.0; ABT-089) – nicotinic acetylcholine receptor agonist [115] Psilocybin (CYB-001; INT0052/2020) – non-selective serotonin receptor agonist and psychedelic hallucinogen [116] Research programme: depression and anxiety therapies - Roche/Vernalis – undefined mechanism of action [117] Research programme: GPCR modulators - Nxera Pharma – various actions [118] Research programme: monoamine oxidase A inhibitors - CeNeRx BioPharma – monoamine oxidase A (MAO-A) inhibitors [119] Ritanserin (R-55667) – serotonin 5-HT2 receptor antagonist and other actions [120] Robalzotan (AZD-7371; NAD-299) – serotonin 5-HT1A receptor antagonist [121] RS-127445 (MT-500) – serotonin 5-HT2B receptor antagonist [122] SAX-187 (WAY-181187) – serotonin 5-HT6 receptor agonist [123] Sergolexole (LY-281067) – serotonin 5-HT2 receptor antagonist [124] Siramesine (LU-28179) – sigma σ2 receptor agonist [125] SKL-PSY (FZ-016) – serotonin 5-HT1A receptor agonist [126] SSR-241586 (SSR241586) – neurokinin NK2 and NK3 receptor antagonist [127] SUN-8399 – serotonin 5-HT1A receptor agonist [128] Suriclone (RP-31264) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [129] Talaglumetad (LY-544344) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (eglumetad prodrug) [130] Tiagabine (A-70569; CEP-6671; Gabitril; NO-050328; NO-328) – GABA transporter 1 (GAT-1) blocker and GABA reuptake inhibitor Troriluzole (BHV-4157; Dazluma; FC-4157; trigriluzole) – various actions (riluzole prodrug) [131] Vestipitant (GW-597599) – neurokinin NK1 receptor antagonist [132] Zabaglurant (TMP-301; TMP301; Heptares 25; HTL-0014242; HTL14242) – metabotropic glutamate mGlu5 receptor negative allosteric modulator [133] Zalospirone (WY-47846) – serotonin 5-HT1A receptor agonist [134]
Even snRNAs and snoRNAs themselves undergo series of modification before they become part of functional RNP complex. This is done either in the nucleoplasm or in the specialized compartments called Cajal bodies. Their bases are methylated or pseudouridinilated by a group of small Cajal body-specific RNAs (scaRNAs), which are structurally similar to snoRNAs.
=== Phase separation revisited === Advances in confocal microscopy at the end of the 20th century identified proteins, RNA or carbohydrates localising to many non-membrane bound cellular compartments within the cytoplasm or nucleus which were variously referred to as 'puncta/dots', 'signalosomes', 'granules', 'bodies', 'assemblies', 'paraspeckles', 'purinosomes', 'inclusions', 'aggregates' or 'factories'. During this time period (1995-2008) the concept of phase separation was re-borrowed from colloidal chemistry & polymer physics and proposed to underlie both cytoplasmic and nuclear compartmentalization. Since 2009, further evidence for biomacromolecules undergoing intracellular phase transitions (phase separation) has been observed in many different contexts, both within cells and in reconstituted in vitro experiments. The newly coined term "biomolecular condensate" refers to biological polymers (as opposed to synthetic polymers) that undergo self assembly via clustering to increase the local concentration of the assembling components, and is analogous to the physical definition of condensation. In physics, condensation typically refers to a gas–liquid phase transition.
Sources: en.wikipedia.org
A multistep biochemical pathway like the Krebs cycle did not just self-organize on the surface of a mineral; it must have been preceded by simpler pathways. The Wood–Ljungdahl pathway is compatible with self-organization on a metal sulfide surface. Its key enzyme unit, carbon monoxide dehydrogenase/acetyl-CoA synthase, contains mixed nickel-iron-sulfur clusters in its reaction centers and catalyzes the formation of acetyl-CoA. However, prebiotic thiolated and thioester compounds are thermodynamically and kinetically unlikely to accumulate in the presumed prebiotic conditions of hydrothermal vents. One possibility is that cysteine and homocysteine may have reacted with nitriles from the Strecker reaction, forming catalytic thiol-rich polypeptides. It has been suggested that the iron-sulfur world hypothesis and RNA world hypothesis are not mutually exclusive as modern cellular processes do involve both metabolites and genetic molecules.
==== Cibacron Blue F3GA ==== Cibacron Blue F3GA, Procion Blue HB, or Reactive blue 2 is a purinergic receptor antagonist, such as P2Y purinoceptor, and also an ATP receptor channels antagonist. It has a formula of C29H20ClN7O11S3 and a molecular weight of 774.2 g/mol. Cibacron blue is soluble in water and DMSO, however insoluble in ethanol. In water, saturated concentration is reached at 12.92 mM with the help of sonication. Cibacron Blue F3GA has a wide specificity for nucleotide-binding proteins or just a stereoselectivity electrostatic binding. It can be used to purify interferons, dehydrogenases, kinases, and serum albumin. For example, interferon purification from human gingival fibroblast extract using Cibacron Blue F3G-A on poly(2-hydroxyethyl methacrylate), the supporting matrix, in the form of cryogels. It has shown 97.6% purity of interferon.
As of 2012, at least eight mummified human remains have been recovered from the Douzlakh Salt Mine at Chehr Abad in northwestern Iran. Due to their salt preservation, these bodies are collectively known as Saltmen. Carbon-14 testing conducted in 2008 dated three of the bodies to around 400 BC. Later isotopic research on the other mummies returned similar dates, however, many of these individuals were found to be from a region that is not closely associated with the mine. It was during this time that researchers determined the mine suffered a major collapse, which likely caused the death of the miners. Since there is significant archaeological data that indicates the area was not actively inhabited during this time period, current consensus holds that the accident occurred during a brief period of temporary mining activity.
== Causes == The NIH states: "The causes of most cases of reactive hypoglycemia are still open to debate. Some researchers suggest that certain people may be more sensitive to the body's normal release of the hormone epinephrine, which causes many of the symptoms of hypoglycemia. Others believe deficiencies in glucagon secretion might lead to reactive hypoglycemia. Several other hormones are responsible for modulating the body's response to insulin, including cortisol, growth hormone and sex hormones. Untreated or under-treated hormonal disorders such as adrenal insufficiency (see also Addison's disease) or growth hormone deficiency can therefore sometimes cause insulin hypersensitivity, and reactive hypoglycemia. Stomach bypass surgery or hereditary fructose intolerance are believed to be causes, albeit uncommon, of reactive hypoglycemia. Myo-inositol or 1D-chiro-inositol withdrawal can cause temporary reactive hypoglycemia. There are several kinds of reactive hypoglycemia:
=== Synthetic steroids and sterols === A variety of synthetic steroids and sterols have also been contrived. Most are steroids, but some nonsteroidal molecules can interact with the steroid receptors because of a similarity of shape. Some synthetic steroids are weaker or stronger than the natural steroids whose receptors they activate. Some examples of synthetic steroid hormones:
Sources: en.wikipedia.org
==== Applications in pharmaceutical industry ==== Oral drug delivery: Emulsions may provide an efficient means of administering drugs that are poorly soluble or have low bioavailability or dissolution rates, increasing both dissolution rates and absorption to increase bioavailability and improve bioavailability. By increasing surface area provided by an emulsion, dissolution rates and absorption rates of drugs are increased, improving their bioavailability. Topical formulations: Emulsions are widely utilized as bases for topical drug delivery formulations such as creams, lotions and ointments. Their incorporation allows lipophilic as well as hydrophilic drugs to be mixed together for maximum skin penetration and permeation of active ingredients. Parenteral drug delivery: Emulsions serve as carriers for intravenous or intramuscular administration of drugs, solubilizing lipophilic ones while protecting from degradation and decreasing injection site irritation. Examples include propofol as a widely used anesthetic and lipid-based solutions used for total parenteral nutrition delivery. Ocular Drug Delivery: Emulsions can be used to formulate eye drops and other ocular drug delivery systems, increasing drug retention time in the eye and permeating through corneal barriers more easily while providing sustained release of active ingredients and thus increasing therapeutic efficacy.
=== McLafferty rearrangement === The McLafferty rearrangement can occur in a molecule containing a keto-group and involves β-cleavage, with the gain of the γ-hydrogen atom. Ion-neutral complex formation involves bond homolysis or bond heterolysis, in which the fragments do not have enough kinetic energy to separate and, instead, reaction with one another like an ion-molecule reaction.
== Hazards associated with MAP == Successful delivery of fresh produce in MAP is not without potential hazards due to incompatibility of MAP film to the fruit or vegetable it is intended to keep fresh and high dependence on good temperature management. Undesirable consequences of incompatible film and/or high temperatures may be "anaerobic respiration with the accumulation of acetaldehyde, ethanol, ethyl acetate, and lactic acid, all of fermentation, contributing to the development of off odors, off flavors, and disuse deterioration." Extreme changes in O2 and CO2 to intolerable levels often occur when fresh produce packed in improper MAP is exposed to higher than recommended temperatures during shipment and distribution. Other undesirable effects of improper MAP are initiation or aggravation of certain physiological disorders, irregular fruit ripening, and increased susceptibility to decay following physiological damage."
February 14, 2013: European Union The recession in the Eurozone economy deepens with a fall of 0.6% in GDP in the fourth quarter of 2012. Of the major economies, Germany shrinks by 0.6%, France by 0.3% and Italy by 0.9%. The economy of the 27 members of the EU, including non-Eurozone members such as Denmark and the UK, shrinks by 0.5%.
Partial-thickness: The more common type involves removing a thin layer of skin from a healthy part of the body (the donor section). Full-thickness: Involves excising a defined area of skin, with a depth of excision down to the fat. The full thickness portion of skin is then placed at the recipient site. A full-thickness skin graft is more risky, in terms of the body accepting the skin, yet it leaves only a scar line on the donor section, similar to a Cesarean-section scar. In the case of full-thickness skin grafts, the donor section will often heal much more quickly than the injury and causes less pain than a partial-thickness skin graft. A partial thickness donor site must heal by re-epithelialization which can be painful and take an extensive length of time.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.